Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol).The settlement agreement...
Esperion Therapeutics ESPR incurred a fourth-quarter 2024 loss of 10 cents per share (excluding one-time expenses of loss on extinguishment of debt and exchange transaction), which was narrower than the...
The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.
U.S. stock markets witnessed an impressive rally in 2024 after an astonishing bull run in 2023. Following the 24.2% ascent in 2023, the S&P 500 rallied 23.3% last year. The Dow and the Nasdaq Composite...
Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease mechanisms and develop tests, therapies and technologies to advance personalized medicine. Companies...
With small-cap stocks surging in response to Donald Trump's re-election and the Federal Reserve's rate cut, investors can tap into this momentum through three distinct ETFs: VBK, DWAS, and UWM, each offering...